Abbott Laboratories (TSX:ABT)
18.52
+0.32 (1.76%)
Oct 30, 2026, 3:49 PM EDT
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $13.01B USD in the quarter ending September 30, 2026, with 14.46% growth. This brings the company's total for the last twelve months to $48.23B, up 10.00% year-over-year. In the year 2025, Abbott Laboratories had annual revenue of $44.33B with 5.67% growth.
Revenue (ttm)
$48.23B
Revenue Growth
+10.00%
P/S Ratio
3.74
Revenue / Employee
$395.32K
Employees
122,000
Market Cap
256.41B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Abbott Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.33B | 2.38B | 5.67% |
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | 31.90B | 1.33B | 4.34% |
| Dec 31, 2018 | 30.58B | 3.19B | 11.64% |
| Dec 31, 2017 | 27.39B | 6.54B | 31.35% |
| Dec 31, 2016 | 20.85B | 448.00M | 2.20% |
| Dec 31, 2015 | 20.41B | 158.00M | 0.78% |
| Dec 31, 2014 | 20.25B | 590.00M | 3.00% |
| Dec 31, 2013 | 19.66B | 607.00M | 3.19% |
| Dec 31, 2012 | 19.05B | -2.36B | -11.01% |
| Dec 31, 2011 | 21.41B | -13.76B | -39.13% |
| Dec 31, 2010 | 35.17B | 4.40B | 14.31% |
| Dec 31, 2009 | 30.76B | 1.24B | 4.19% |
| Dec 31, 2008 | 29.53B | 3.61B | 13.94% |
| Dec 31, 2007 | 25.91B | 3.44B | 15.30% |
| Dec 31, 2006 | 22.48B | 138.51M | 0.62% |
| Dec 31, 2005 | 22.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Profound Medical | 27.10M |
| Perimeter Medical Imaging AI | 3.03M |
| Cheelcare | 2.32M |
| Conavi Medical | 845.00K |
| Theralase Technologies | 802.46K |
| Frequency Exchange | 647.43K |
| MedX Health | 569.79K |
| Ventripoint Diagnostics | 147.77K |
Abbott Laboratories News
- 48 minutes ago - Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System - PRNewsWire
- 2 days ago - FDA posts adverse event report for Abbott’s Tendril SDX - TheFly
- 3 days ago - Abbott initiates pivotal trial for Cephea device - TheFly
- 3 days ago - Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease - PRNewsWire
- 5 days ago - Abbott cut to Hold at Argus amid reimbursement uncertainty, competitive pressure - TheFly
- 5 days ago - Abbott downgraded to Hold from Buy at Argus - TheFly
- 6 days ago - Abbott announces commercial availability of Oncodetect residual disease test - TheFly
- 6 days ago - Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment - PRNewsWire